Skip to main content
大禹生物 logo

大禹生物 — Investor Relations & Filings

Ticker · 920970 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 384 across all filing types
Latest filing 2022-07-21 Board/Management Inform…
Country CN China
Listing Beijing Stock Exchange 920970

About 大禹生物

http://www.sxdysw.cn/

Shanxi Dayu Biological Assistance Co., Ltd. specializes in the research, development, and production of advanced animal nutrition and health solutions. The company focuses on the manufacturing of feed additives, micro-ecological preparations, and biological feed products. Its core portfolio includes probiotics, enzyme preparations, and functional premixes designed to enhance livestock immunity, improve feed conversion rates, and promote sustainable farming practices. By leveraging biotechnology, the firm provides integrated solutions for the aquaculture and animal husbandry sectors, emphasizing scientific innovation and product quality to support the modernization of the agricultural supply chain.

Recent filings

Filing Released Lang Actions
独立董事关于第三届董事会第四次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on proposals discussed at a board meeting, specifically regarding a stock price stabilization plan and a share repurchase plan. It includes legal compliance statements and the directors' agreement to submit these proposals to the shareholders' meeting. The content focuses on board/management opinions and approvals rather than financial results, audit, or regulatory filings. It is not a full report but a formal board-related announcement. Therefore, the document fits best under Board/Management Information (MANG). The document length is short and does not contain financial statements or detailed financial data, so it is not an Annual Report or Interim Report. It is not a Regulatory Filing or Report Publication Announcement since it contains substantive board opinions and approvals.
2022-07-21 Chinese
第三届董事会第四次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the fourth meeting of the third board of directors of Shanxi Dayu Biological Engineering Co., Ltd. It details the meeting's attendance, the agenda items discussed, voting results, and mentions that some proposals will be submitted to the shareholders' meeting for approval. The content focuses on board decisions, including stock price stabilization measures, share repurchase plans, and authorization for the board to handle repurchase matters. There is no financial data or detailed report content, but rather a summary of board meeting decisions. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors or senior management.
2022-07-21 Chinese
关于触发稳定股价措施启动条件的提示性公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Shanxi Dayu Bioengineering Co., Ltd. regarding the triggering of conditions to initiate stock price stabilization measures following its recent listing on the Beijing Stock Exchange. It details the criteria for triggering these measures, the specific triggering event, and the company's plan to announce the stabilization measures. The document is short (858 characters) and is an announcement related to stock price stabilization measures, not a financial report or detailed filing. It does not contain financial statements or detailed financial data. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2022-07-17 Chinese
关于延长公司股东股份锁定期的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from Shanxi Dayu Biological Engineering Co., Ltd. regarding the extension of the lock-up period for shares held by controlling shareholders, actual controllers, directors, and senior management. It details the commitments and restrictions on share transfers and the automatic extension of the lock-up period by 6 months due to certain conditions being triggered. The content focuses on shareholding restrictions and lock-up period extension rather than financial results, management changes, or other report types. It is not a financial report, earnings release, or management discussion. It is a regulatory announcement about share lock-up extension, which fits best under Regulatory Filings (RNS) as it does not fit other more specific categories and is not a report publication announcement or a proxy solicitation. The document length is 4083 characters, which is relatively short but contains substantive content about share lock-up extension, not just a notice of report publication.
2022-07-17 Chinese
关于完成工商变更登记及公司章程备案并取得营业执照的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the completion of business registration changes and company charter filing, including obtaining a new business license. It details changes in company type and registered capital following board and shareholder meetings. The document is short (827 characters) and serves as a formal notification of these corporate changes rather than a detailed report or financial statement. It does not contain financial data, audit information, or detailed management discussion. It is not a report itself but an announcement of corporate registration updates. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2022-07-13 Chinese
投资者关系活动记录表
Call Transcript Classification · 95% confidence The document is an investor relations activity record for a 2022 investor online meeting focused on the 2021 annual results. It includes detailed Q&A about the company's business, financial performance, cash flow, and outlook for 2021. The content is a transcript or summary of an earnings explanation session, not a formal earnings release or full annual report. The document length is 3450 characters, which is relatively short but contains substantive financial discussion and management commentary. This matches the characteristics of a Call Transcript (CT) or an investor earnings explanation session rather than a brief announcement or a full report. Given the detailed Q&A format and focus on 2021 financial results, the best fit is Call Transcript (CT).
2022-06-23 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.